Actavis Seeks En Banc Review Of Fed. Circ. Endo IP Ruling
Actavis Inc. urged the Federal Circuit on Wednesday to rehear en banc the company's appeal of a ruling that settlements allowing the sale of generic versions of Endo Pharmaceuticals Inc.'s painkiller...To view the full article, register now.
Already a subscriber? Click here to view full article